Acyclic ethylenediamine derivatives as substance p receptor antagonists
CA 2123403 C · Owner: Pfizer Limited · Inventors: O'Neill, Brian T.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to novel acyclic ethylenediamine derivatives of nitrogen containing heterocyclic compounds and specifically, to compounds of formula (I) wherein R1 R2, R3, R4, R5 and , R6 are defined as in the specification. It also relates to novel intermediates used in the synthesis of such derivatives. Compounds of formula (I) and their pharmaceutically acceptable salts are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 18, 1992 and granted February 5, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 18, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 18, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.